This course is developed by Medscape Education Global.
Medscape is one of the leading digital platforms for medical
education. A comprehensive array of innovative formats, in multiple
languages, insures the right educational solution is available to best
achieve desired objectives—from text-based articles to
state-of-the-art multimedia formats and the most sophisticated
simulation environments. Activity formats include Clinical Insights,
Expert Perspective, Instructional Series Programming, Next-Generation
Symposia, Patient-Case Approaches, including Simulation and Clinical Advances.
Summarizing selected highlights from the ADA annual congress 2020
with respect to the prevention of macrovascular complications in
diabetes, the expert cardiologist Dr Mark Petrie from Glasgow, UK,
reviews the top line results from the VERTIS trial with ertugliflozin,
a new meta-analyis of SGLT2 inhibators, an update from DAPA-HF and the
DEVOTE trial. He also comments on the findings from the HypoDeg CGM
substudy in patients with type 1 diabetes, comparing the incidence of
hypoglycemia of the second-generation basal insulin degludec with
insulin glargine as well as emerging profile of the once weekly
insulin icodec and pleotropic effects of GLP-1 RAs.
Made for: Diabetologists, Endocrinologists, Cardiologists,
Primary Care Physicians
Disease areas: Diabetes
Developed by: Medscape